Form 4 for ABOS Acumen Pharmaceuticals, Inc.
Accepted 2025-01-23 00:00:00 ET · period of report 2025-01-21 · accession 0001576885-25-000037 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-01-23 | 2025-01-21+ | ABOS | Zuga Matt | CFO, Chief Business Off | S - Sale | $1.70 | -33.3K | 231.7K | -13% | -$56.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-21 | S | D | 4,364 | $1.60 | 260,646 | D | — | — | (F1) Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. (F2) The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.5800 to $1.6100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2025-01-23 | S | D | 28,902 | $1.72 | 231,744 | D | — | — | (F3) Represents the number of shares sold by the Reporting Person in connection with the vesting of RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2024. (F4) The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.6705 to $1.7699. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |